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Achondroplasias are the most common genetic
forms of dwarfism in humans. They are associ-
ated with activating mutations in FGFR3, which
signal through the Stat and MAPK pathways in
a ligand-independent manner to impair chon-
drocyte proliferation and differentiation. Snail1
has been implicated in chondrocyte differentia-
tion as it represses Collagen II and aggrecan
transcription in vitro. Here we demonstrate that
Snail1 overexpression in the developing bone
leads to achondroplasia in mice. Snail1 acts
downstream of FGFR3 signaling in chondro-
cytes, regulatingbothStat andMAPKpathways.
Moreover, FGFR3 requires Snail1 during bone
development and disease as the inhibition of
Snail1 abolishes its signaling even through
achondroplastic- and thanatophoric-activating
FGFR3 forms. Significantly, Snail1 is aberrantly
upregulated in thanatophoric versus normal car-
tilages from stillborns. Thus, Snail activity may
likely be considered a target for achondroplasia
therapies.
INTRODUCTION
Endochondral ossification is a multistep process in which
cartilage is replaced by bone. During this process, bones
grow in length at the growth plate, where chondrocytes
sequentially undergo proliferation, prehypertrophy, and
hypertrophy. When the proliferating chondrocytes stop
dividing, they differentiate into hypertrophic chondrocytes
before undergoing apoptosis. This population promotes
the mineralization of the surrounding matrix, directing
perichondrial cells to become osteoblasts and attracting
blood vessels that allow the osteoblasts to invade the
cartilage mold and lay down a true bone matrix (Karsenty
and Wagner, 2002; Kronenberg, 2003). Thus, the control872 Developmental Cell 13, 872–883, December 2007 ª2007 Eof longitudinal growth in long bones is mediated by a com-
plex interplay of regulatory networks that involve the
chondrocytes in the growth plate and the perichondrial
cells in the perichondrium.
FGF signaling is one of the main pathways that control
bone development (Ornitz and Marie, 2002). In particular,
signaling through the FGFR3 is instrumental in controlling
bone size by inhibiting chondrocyte proliferation and
differentiation (L’Hoˆte and Knowles, 2005). Indeed,
disruption of FGFR3 in mice causes severe bone dysplasia
with enhanced growth, due to the expansion of proliferat-
ing chondrocytes within the growth plate (Colvin et al.,
1996; Deng et al., 1996). In contrast, activating mutations
lead to the principal forms of dwarfism in humans such as
achondroplasia (ACH), thanatophoric dysplasia types I
and II (TDI and TDII), and hypochondroplasia (HCH) (Rous-
seau et al., 1994, 1995, and 1996; Shiang et al., 1994;
Bellus et al., 1995a and 1995b, Prinos et al., 1995; Tavor-
mina et al., 1995a and 1995b). Studies in mouse models
have revealed that signaling through FGFR3 inhibits chon-
drocyte proliferation and differentiation (Chen et al., 1999;
Naski et al., 1996; Wang et al., 1999). This growth inhibition
associated with FGF signaling is specific to chondrocytes
(Wang et al., 2001) and is mediated by STAT1, the phos-
phorylation and subsequent nuclear translocation of
which activates cell cycle inhibitor p21Waf1/Cip1 (Su et al.,
1997; Li et al., 1999; Sahni et al., 1999; Legeai-Mallet
et al., 2004). The milder cartilage and bone phenotype of
Stat1 null mice when compared to that of FGFR3 null
mice suggested that FGFR3 signaling also interacts with
other pathways during skeletal development. Indeed,
FGFs also activate the MAPK pathway in chondrocytes,
which affects longitudinal growth by regulating hypertro-
phic chondrocyte differentiation and matrix deposition
(Murakami et al., 2000 and 2004).
The expression of Snail1 in mesenchymal condensa-
tions and hypertrophic chondrocytes, coupled with the
fact that Snail can be induced by FGF in other develop-
mental systems (Nieto et al., 1992; Seki et al., 2003; Nieto,
2002), prompted us to study the role of Snail1 in chondro-
genesis. We show that not only is Snail1 expressed inlsevier Inc.
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but it is also found in the prehypertrophic population. To
further understand Snail1 function, we generated a trans-
genic mouse model in which we can activate Snail1
protein function. We show that deregulation of Snail1
activity in the developing bone leads to achondroplasia
in mice. Indeed, we demonstrate that Snail1 lies down-
stream of FGF signaling in chondrocytes and that in the
absence of Snail1, signaling through FGFR3 is abolished
even when the receptor is constitutively active as in the
ACH and TDII mutant forms. Thus, our data indicate that
Snail1 is essential to transduce FGFR3 signaling during
chondrogenesis.
RESULTS
Aberrant Snail1 Activation at Fetal Stages Induces
a Dwarfism-like Phenotype
To gain further insight into the role of Snail in skeletal
development, we generated a transgenic mouse model
expressing a chimeric construct in which Snail1 could
be activated by tamoxifen (Snail1-ER; see Experimental
Procedures). This inducible system is appropriate to ana-
lyze transcription factors’ activity, since despite its consti-
tutive expression the exogenous protein is only active
after nuclear translocation upon tamoxifen administration
(Feil et al., 1996; Boutet et al., 2006).
Taking advantage of the strong repression of E-
cadherin transcription by Snail1 (Cano et al., 2000), we
assessed the activity of the chimeric protein in preimplan-
tation transgenic embryos where E-cadherin is crucial for
compaction of the morula (Riethmacher et al., 1995).
Snail1 activation completely repressed E-cadherin tran-
scription, mimicking the E-cadherin mutant phenotype
and confirming that the chimeric protein was fully active
in embryos (see Figure S1 in the Supplemental Data avail-
able with this article online). We selected a transgenic line
with significant exogenous protein expression in the de-
veloping bones to analyze the effect of Snail1 aberrant ac-
tivation during chondrogenesis (Figure 1). Snail1 was acti-
vated by administering tamoxifen to pregnant mothers from
12.5 dpc, and embryos were then analyzed at 18.5 dpc.
All embryos developed short limbs but a normal-sized
head (Figure 1A). Closer examination of the dissected
limbs confirmed the reduced length of the long bones,
and Alcian blue/Alizarin red staining of the femurs showed
a reduced growth plate (brackets in Figures 1B and 1C).
Exogenous Snail1 protein was readily translocated to
the nucleus within 2 days of tamoxifen administration
(Figures 1D–1G). Hematoxylin staining of paraffin sections
revealed a highly disorganized growth plate, probably re-
flecting altered proliferation and maturation (Figures 2A–
2D). Moreover, the columnar structure of proliferative
chondrocytes was lost (see insets in Figures 2C and 2D).
We observed graded phenotypes that correlated with
the expression level of the exogenous Snail1 protein
(Figure S2). The bones in Figure 2 correspond to embryos
of intermediate phenotype, where the size of both the pro-
liferating and hypertrophic zones was greatly reducedDevelopme(Figure 2E). This phenotype is reminiscent of the achon-
droplasia-type dwarfism (Horton, 2006).
The reduced length might reflect diminished proliferation
or increased cell death. To assess whether proliferation
was affected in these mice, we analyzed the phosphoryla-
tion of histone H3 to visualize the mitotic cells (Prigent and
Dimitrov, 2003). There was significant phospho-H3 stain-
ing in the growth plate of the control embryos in a zone ad-
jacent to the hypertrophic chondrocytes (Figures 2F–2H).
However, in transgenic embryos that were administered
tamoxifen, the phospho-H3-stained cells were scattered
(Figure 2H) as they were reduced in number to around
30% in the same zone (Figure 2I). Cell death analysis by
TUNEL staining and quantification of labeled cells did not
reveal differences in wild-type and transgenic embryos
regardless of tamoxifen administration (Figure S3). These
results indicate that Snail1 activation impairs cell prolifera-
tion in the growth plate without affecting cell survival.
The Endogenous Expression of Snail1 Is
Compatible with Its Inhibiting Chondrocyte
Proliferation
Since Snail1 is normally expressed during chondrogene-
sis (Nieto et al., 1992; Seki et al., 2003), we assessed
whether its endogenous expression pattern is coincident
with the stages of diminished cell proliferation. When
Snail1 expression was compared with that of other
markers for different cell populations, we observed that
in addition to the condensing mesenchyme and hypertro-
phic chondrocytes (Figures 3A–3C), Snail1 is also tran-
scribed in the prehypertrophic chondrocyte population
(Figure 3D). Snail1 transcripts coincided with those of
the parathyroid hormone-related peptide receptor gene
(PPR; Figure 3F), a specific marker of the prehypertrophic
chondrocytes (Lee et al., 1995) and importantly, also with
high levels of Fgfr3 gene expression (Figure 3E), crucial in
controlling bone size by inhibiting chondrocyte prolifera-
tion (L’Hoˆte and Knowles, 2005). Similarly, there was
colocalization of Snail1 expression with the last stage of
type II collagen transcription (Figure 3H) that is then lost
before hypertrophic differentiation, and which is concur-
rent with a switch to Type X collagen secretion (Karsenty
and Wagner, 2002). These data indicated that the endog-
enous expression of Snail1 is compatible with its exerting
an influence on chondrocyte proliferation.
Snail1 Inhibits Chondrocyte Proliferation
by Activating the Stat1 Pathway
Achondroplasia in humans and mice is associated with
activating mutations in FGFR3, which signals through
Stat1. This transcription factor is the mediator of the
cell-type-specific growth-inhibitory activity of FGFR3 on
chondrocytes (Sahni et al., 1999; Wang et al., 2001). Since
tamoxifen-treated transgenic embryos displayed a dwarf
phenotype, we analyzed whether Stat1 activation was
responsible for the low proliferation observed in the devel-
oping bones. Indeed, activation of Stat1 can be detected
by its nuclear translocation (Figure 4D, see inset), and it is
accompanied by a strong increase in p21 transcriptionntal Cell 13, 872–883, December 2007 ª2007 Elsevier Inc. 873
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Snail Mediates FGFR3 SignalingFigure 1. Snail1 Activation at Fetal Stages Induces a Dwarfism-like Phenotype
(A) Transgenic embryos expressing a tamoxifen-inducible Snail construct (Snail1-ER) display shorter limbs and body but a normal-sized head when
analyzed at 18.5 dpc after tamoxifen administration (see Experimental Procedures).
(B and C) Alcian Blue-Alizarin Red S staining shows a reduced growth plate in the femur of tamoxifen-treated Snail1-ER embryos (brackets).
(D–G) Exogenous Snail1 protein is expressed in the cytoplasm of the transgenic bones (F) and is translocated to the nucleus upon tamoxifen (TAM)
administration (G), as seen with an anti-human estrogen receptor antibody (hER). Scale bar indicates 1 mm in (A), 500 mm in (B), and 100 mm in (D)–(G).(Figure 4E), the cell cycle inhibitor target of Stat1 in chon-
drocytes (Su et al., 1997; Sahni et al., 1999). However, the
transcription of the Stat1 gene is not altered in the tamox-
ifen-treated transgenic bones, suggesting that the regula-
tion of Stat activity is at the level of nuclear translocation
(Figure S4). Interestingly, endogenous Snail1 expression
was associated with high levels of nuclear Stat1 both in
the perichondrium (compare Figure 4G with Figure 4J)
and the hypertrophic chondrocytes (compare Figure 4H
with Figure 4K). These data indicate that Stat1 activation
appears to be coupled to Snail1 activity during normal
chondrogenesis.
Snail1 Is Downstream of FGFR3 Signaling
in Chondrocytes
Sustained Snail1 activation induces a strikingly similar
phenotype to that observed in humans and mice carrying
activating mutations in FGFR3. Therefore, we wondered874 Developmental Cell 13, 872–883, December 2007 ª2007 Ewhether Snail1 might be a target of FGF signaling during
chondrogenesis. This possibility was analyzed in cultures
of dissociated 14.5 dpc hindlimb cells from wild-type
embryos, which differentiated to chondrocytes upon
exposure to BMP-2 (Figure 5A; Valcourt et al., 1999).
Differentiated chondrocytes form prototypical nodules
after 5 days in culture, and they express Type II but not
Type I collagen (Figure 5A). When differentiated chondro-
cytes were treated with FGF, the transcription of p21
increased, indicating that the cells expressed FGFR3 in
culture (Figure 5B). This increase was significantly higher
when FGF was added after transfecting the cells with
a wild-type version of FGFR3 (Figure 5B). When chondro-
cytes were transfected with the ligand-independent
mutant versions of FGFR3 present in ACH (G374R; Wang
et al., 1999) or TDII (K644E; Li et al., 1999), constitutively
high expression of p21was registered. The levels of Snail1
expression followed a similar trend of those of p21 afterlsevier Inc.
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Snail Mediates FGFR3 SignalingFigure 2. The Dwarfism-like Phenotype following Snail1 Aberrant Activation Is Associated with a Reduced Growth Plate and a
Decrease in Chondrocyte Proliferation
(A–D) Histological sections of transgenic bones after tamoxifen administration reveal the disorganization of the growth plate in which the typical chon-
drocyte columns are almost completely absent (compare insets in [C] and [D]).
(E) The proliferating and hypertrophic chondrocyte populations are very much reduced.
(F–I) The phospho-histone-3-labeled cells are greatly reduced in the growth plates of tamoxifen-treated transgenic embryos, indicating a much lower
proliferation rate (insets in [H] and [I]).
(J) Phospho-histone-3-positive cells were quantified and represented as the percentage of total cell number. Results are the mean values ± SD from
12 tamoxifen-treated transgenic embryos plus five per each control condition (three sections per embryo; [E]) and from five embryos per experimental
condition (five sections each; [J]). Scale bars indicate 100 mm.transfection with the wild-type or the mutant FGFR3 forms
(Figure 5C). In addition, Snail1 expression was highest
when chondrocytes expressed the TDII FGFR3 mutant,
as were the levels of p21 transcription (Figure 5B). Consid-
ering that p21 was induced in the transgenic mice upon
Snail activation and that this activation does not modify
Fgfr3 expression (Figure S5), our results indicate that
Snail1 is a downstream target of FGFR3 signaling that
regulates the Stat1 pathway. The regulation is at the level
of nuclear translocation as described during FGFR3
signaling (Su et al., 1997). Indeed, the levels of Stat1 tran-
scripts remain unaffected (Figure 5E) as they do after
Snail1 activation in transgenic mice (Figure S4).
Differentiated collagen II-positive chondrocytes express
Snail1 transcripts as they do in the developing bone (see
Figures 3D and 3H), and the protein is localized in the
nucleus (Figure 5F). The upregulation of Snail1 expression
observed upon TDII-FGFR3 transfection results in an
increase in nuclear Snail1 protein (250% increase;
Figure 5F). Snail2, the other very similar Snail family mem-
ber, was not activated by FGF or TDII-FGFR3 (Figure 5D).
This activating form of the receptor was unable to induceDevelopmeSnail1 or p21 expression in the epithelial kidney MDCK
cell line (data not shown), suggesting that the pathway
may be specific for chondrocytes.
Snail1 Activation Impairs Hypertrophic
Chondrocyte Differentiation by Activating
the MAPK Pathway
In addition to reduced proliferation, we also observed
a narrower hypertrophic zone in the growth plates of
tamoxifen-treated Snail1-ER embryos (Figure 2E), as
well as a delay in the formation of the secondary ossifica-
tion centers when the transgenic animals were treated
postnatally (Figure S6). Both these defects, impaired
hypertrophic chondrocyte differentiation and diminished
proliferation, have also been associated with activating
mutations of FGFR3 in mice and humans (Iwata et al.,
2000; Legeai-Mallet et al., 2004). Indeed, FGF signaling
coordinates the onset of chondrocyte differentiation with
the arrest of chondrocyte proliferation in the developing
growth plate (Dailey et al., 2003). Thus, we assessed the
degree of chondrocyte differentiation by analyzing the ex-
pression of Type X collagen, a marker of the hypertrophicntal Cell 13, 872–883, December 2007 ª2007 Elsevier Inc. 875
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restricted to prehypertrophic chondrocytes. The expres-
sion of the Type X collagen was significantly weaker in
the developing bones of transgenic embryos in which
Snail1 was activated (Figures 6A–6D). This decrease
may be due to a direct effect of Snail1 on Type X collagen
expression or to its role on chondrocyte differentiation. In
addition, Sox9 expression failed to be downregulated
Figure 3. Snail1 Expression in Developing Hindlimbs
(A–C) Snail1 expression in embryonic hindlimbs from 12.5 dpc to
16.5 dpc. Snail1 is first expressed in the mesenchymal condensations
that will form the cartilage and bone. From 14.5 dpc, Snail1 transcripts
are detected in prehypertrophic and hypertrophic chondrocytes in
a gradient fashion and in the perichondrium.
(D–I) Snail1 expression in 18.5 dpc embryonic hindlimbs compared
with that of specific markers of the main cell populations in the growth
plate. A side-by-side comparison indicates that Snail1 is expressed in
both prehypertrophic and hypertrophic chondrocytes (see inset in [D]).
Markers: Fgfr3; Coll1a1 (osteoblats), Coll2a1 (proliferating and prehy-
pertrophic chondrocytes), and Coll10a1 (hypertrophic chondrocytes)
corresponding to Type I, Type II, and Type X collagens, respectively;
PPR, the parathyroid hormone-related peptide receptor. rc, resting
chondrocytes; pc, proliferative chondrocytes; phc, prehypertrophic
chondrocytes; hc, hypertrophic chondrocytes; tb, trabecular bone;
p, perichondrium. Scale bar indicates 100 mm.876 Developmental Cell 13, 872–883, December 2007 ª2007 E(Figures 6E–6J) in the resting and proliferating chondro-
cytes (compare Figure 6F with Figure 6I) or in the reduced
hypertrophic population (Figures 6G and 6J, red stars).
Other differentiation markers such as Indian hedgehog
(Ihh) and parathyroid hormone-related peptide receptor
(PPR) were also analyzed upon Snail1 activation, and Ihh
transcripts were downregulated (Figure S7) as in other
mouse models of achondroplasia (Naski et al., 1998;
Zhang et al., 2006). Hence, as well as diminishing chon-
drocyte proliferation, Snail1 activation also impairs hyper-
trophic chondrocyte differentiation.
FGF induces Sox9 expression in chondrocytes through
the MAPK (MEK1/Erks) pathway (Murakami et al., 2000).
Considering Snail1 as a downstream target of FGF signal-
ing in chondrocytes and that Sox9 is not downregulated in
hypertrophic chondrocytes upon sustained Snail1 activa-
tion, we analyzed whether the defects on differentiation
observed in the transgenic mice might be due to an
increase in the activity of the MAPK pathway. We differen-
tiated chondrocytes by adding BMP2 to cultures of
hindlimbs from 14.5 dpc Snail1-ER transgenic embryos
(Figures 6K and 6L). After 24 hr in culture in the absence
of tamoxifen, the basal levels of phospho-Erks were main-
tained although they increased after FGF administration.
This indicates that in-vitro-differentiated chondrocytes
respond to FGF signaling. In the presence of tamoxifen
and following the nuclear translocation of the activated
Snail1 transgenic protein (Figure 6K), the levels of phos-
pho-Erks in chondrocytes were constitutively high, re-
gardless of the presence of FGF (Figure 6L). As expected,
the increased level of activated Erks was correlated with
elevated levels of Sox9 protein (Figures 6M and 6N),
confirming that Snail1 also regulates the MAPK pathway
during chondrocyte differentiation.
Snail1 Is Required for FGFR3 Signaling
in Chondrocytes
Having determined that Snail1 is downstream of FGF
signaling in chondrocytes and that it modulates both the
Stat1 and MAPK pathways in the control of chondrocyte
proliferation and differentiation, we asked whether Snail1
was required for FGF signaling through FGFR3. Accord-
ingly, we cotransfected chondrocyte primary cultures
similar to those shown in Figure 5 with the mutant ACH
or TDII FGFR3 forms alone or in combination with different
siRNAs againstSnail1 (Figure 7 and Figure S8). BothSnail1
transcripts and Snail1 protein were highly upregulated
upon transfection of activating forms of FGFR3 in the
absence of FGF (Figure 5F and Figures 7A and 7C). This ex-
pression returned to near-basal levels after transfection of
Snail1 siRNAs, either individually or in combination (Fig-
ures 7A and 7C and Figure S8). Interestingly, the elevated
expression of p21 observed in cells transfected with ACH
or TDII FGFR3 also decreased when Snail1 expression
was inhibited by the different siRNAs (Figure 7B and
Figure S8). Similarly, Erks were activated in ACH- or TDII
FGFR3-expressing chondrocytes, and their activation
levels decreased to the basal state when Snail1 expression
was blocked (Figure 7C). Overexpression of a constructlsevier Inc.
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Snail Mediates FGFR3 SignalingFigure 4. Decreased Proliferation in the Growth Plate of Snail1-ER Embryos Correlates with STAT1 Nuclear Localization and p21
Activation
(A–D) STAT1 is localized in the nucleus of the growth plate cells in tamoxifen-treated transgenic embryos (D).
(E) Quantitative PCR from developing bones shows the increase in p21 transcription upon Snail1 activation (black bar). Results are the mean ± SD of
triplicates from a representative experiment (n = 5).
(F–K) Snail1 expression coincides with STAT1 nuclear localization in both the perichondrium (G and J) and the hypertrophic chondrocytes ([H] and [K]
taken from the same hyperprophic region not visible in [F] and [G]) of wild-type developing bones. Scale bar indicates 100 mm.containing the Snail1 coding region resulted in increased
p21 and pERK expression. When this construct was
expressed together with a Snail1 siRNA designed to target
30 untranslated sequences (siRNA-3), it rescued the action
of the siRNA (Figures 7A–7C). Our data indicate that Snail1
mediates the FGFR3 activity that modulates the two
signaling cascades which coordinate chondrocyte prolif-
eration and differentiation (Figure 7D) even in the situation
that reflects the most severe achondroplastic condition
(TDII) in humans. Indeed, the analysis of TDII (bearing the
K650E mutation in theFgfr3gene) versus normal cartilages
from stillborn individuals indicated that Snail1 was aber-
rantly activated (around 12-fold) in the TDII fetus
(Figure 7E). This result demonstrates that Snail1 induction
occurs when FGFR3 signaling is activated in vivo and that
high Snail1 levels occur in achondroplasia.
DISCUSSION
The results of this study reveal unexpected and important
roles for Snail1 in the control of longitudinal bone growth
under normal and pathological conditions. We demon-
strate here that aberrant Snail1 activation in transgenic
mice is sufficient to induce achondroplasia, the most com-
mon form of human dwarfism. The class of chondrodyspla-
sias known as achondroplasia is produced by activating
point-mutations in FGFR3. These are usually de novoDevelopmemutations that generate phenotypes of different severity,
from the mildest hypochondroplastic condition (HC) to
the lethal form of dwarfism, thanatophoric dysplasia (TD)
(see Ornitz and Marie, 2002; Brodie and Deng, 2003 for
reviews). We show here that Snail1 lies downstream of
FGFR3 signaling, which requires Snail1 for regulating
chondrocyte proliferation and differentiation through the
activation of the Stat1/p21 and MAPK/Erks pathways, re-
spectively. Moreover, Snail1 is an important transcriptional
effector of FGFR3 since even the signaling through the
constitutively active ACH or TDII-FGFR3 is abolished
when Snail1 expression is silenced, as assessed by the
read-outs of both pathways: the cell cycle inhibitor p21
and activated Erks. In addition, as aberrant Snail1 activa-
tion is sufficient to induce achondroplasia, genetic or epi-
genetic alterations influencing Snail expression or activity
may cause this disease independently of mutations in the
FGFR3 gene.
Snail1 and the Control of Chondrocyte
Proliferation
Our data demonstrate that Snail1 activation in developing
mouse bones induces Stat1 nuclear translocation, which
increases the expression of the cell cycle inhibitor p21.
This pathway is known to be mediated by FGFR3 in chon-
drocytes, and it leads to a blockage of cell division and the
initiation of chondrocyte differentiation. Snail1 is not onlyntal Cell 13, 872–883, December 2007 ª2007 Elsevier Inc. 877
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Snail Mediates FGFR3 SignalingFigure 5. Activation of the FGF Pathway Induces Snail1 Expression
(A) Primary cell cultures from 14.5 dpc embryonic limbs were differentiated to chondrocytes by exposure to BMP2. Phase contrast micrographs show
the cells just after setting up the culture and following differentiation. Cells express the chondrocyte marker Collagen II but not the osteoblast marker
Collagen I.
Relative mRNA levels for p21 (B) andSnail1 (C) after activating the FGFR3 pathway by administering FGF either before or after transfection with a wild-
type (wt) or activating ACH-FGFR3 (G374R) or TDII-FGFR3 (K644E) constructs. FGF induces p21 transcription, which is constitutively activated after
transfection with the ligand-independent mutant receptors. The regulation of Snail1 transcription correlates with that of p21, and the TDII mutant in-
duces the highest levels of p21 and Snail1 transcripts.
(D) FGFR3 signaling does not induce Snail2 expression.
(E) FGFR3 signaling does not upregulate Stat1 transcription.
(F) The increase inSnail1 expression upon FGFR3 K644E transfection results in increased levels of nuclear Snail1 protein. Results are the mean values
± SD of triplicates from a representative experiment (n = 4).expressed in the condensing mesenchyme and the hyper-
trophic chondocytes (Nieto et al., 1992; Seki et al., 2003)
but also in the prehypertrophic cell population, compatible
with a role of Snail1 in the attenuation of chondrocyte pro-
liferation. Inhibiting cell proliferation seems to be a com-
mon role for Snail1 in different cell contexts, since it also at-
tenuates the growth of epithelial cells in culture by
increasing the level of p21 expression and directly
repressing Cyclin D2 transcription (Vega et al., 2004). The
effects of Snail1 on proliferation have been considered in
the framework of the epithelial-to-mesenchymal transition
(EMT) both in development and cancer progression878 Developmental Cell 13, 872–883, December 2007 ª2007 El(Barrallo-Gimeno and Nieto, 2005). As such, the cytoskel-
etal modifications and changes in cell shape associated
with the Snail-induced EMT may be incompatible with
proliferation. A decrease in proliferation would favor cell
migration versus division during embryonic development
and tumor invasion versus tumor growth during cancer
progression (Vega et al., 2004). In the developing bone,
Snail1 does not induce an EMT, although it still downregu-
lates cell division. These data indicate that Snail1 can influ-
ence the induction of cell movement and the attenuation of
cell proliferation independently depending on the cell
context.sevier Inc.
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Snail Mediates FGFR3 SignalingFigure 6. Sustained Snail1 Expression Impairs Hypertrophic
Chondrocyte Differentiation by Activating the MAPK Pathway
(A–D) The hypertrophic chondrocyte differentiation marker Type X Col-
lagen is greatly reduced in the growth plate of tamoxifen-treated
Snail1-ER embryos (compare [B] with [D]).
(E–J) Sox9 expression fails to be downregulated. Note its high expres-
sion in the resting chondrocytes (compare [F] with [I]) and in the limits
between the prehypertrohic and hypertrophic populations in tamoxi-
fen-treated Snail1-ER embryos compared to the same region in un-
treated transgenic embryos ([G] and [J], red stars).
(K) Immunofluorescence for hER allows Snail1 transgenic protein visu-
alization. Note its nuclear translocation upon 4OH-TAM administra-
tion.
(L) Western blot analysis showing the levels of activated Erks and Sox9
protein in chondrocytes from Snail1-ER embryos differentiated in vitro.
(M and N) Quantification of western blots confirms the increase in the
levels of activated Erks and Sox9 protein. Results are the mean ± SD
from three independent experiments. ANOVA analysis: ** p < 0.01;
*** p < 0.001.DevelopmenThis study also shows that Snail1 is downstream of the
FGFR3 pathway. The pathway seems to be specific for
Snail1, since Snail2, the other very similar vertebrate Snail
family member, was not induced either by FGF or by acti-
vating FGFR3 mutations. Furthermore, the induction of
Snail1 expression by FGFR3 seems to be specific for
chondrocytes since TDII FGFR3 is unable to induce Snail1
or p21 expression in the epithelial kidney MDCK cell line.
Interestingly, MDCK cells upregulate p21 in response to
Snail1 (Vega et al., 2004), indicating that the failure of
FGFR3 in upregulating p21 and inhibiting cell proliferation
in MDCK cells is due to its failure in inducing Snail1
expression. In these cells, Snail1 is in fact induced by a
different signaling pathway, that of TGF-b (Peinado
et al., 2003). These results may explain why the growth-
inhibitory response to FGF signaling is unique to chondro-
cytes, as FGF is known as a proliferative factor in other cell
types (Wang et al., 2001).
Snail1 is indeed required for the FGFR3-induced prolif-
eration arrest in chondrocytes. Silencing Snail1 blocks the
induction of p21 mediated by the constitutively active
TDII-FGFR3 in cultured chondrocytes, and the phenotype
we observe after Snail1 activation reproduces that of mice
with activating mutations in FGFR3 (Horton, 1997; Ornitz
and Marie, 2002). In relation to this, it is worth mentioning
that in a mouse TDII model bearing the same mutant form
of the receptor, FGFR3 activation unexpectedly increased
chondrocyte proliferation in embryos at 15.5 dpc (Iwata
et al., 2000). However, this effect of the activating mutation
was transient as it was not observed at 18.5 dpc or after
birth (Iwata et al., 2000), the stages at which we have
analyzed our transgenic mice. Since we do not observe
any alteration when the mice were analyzed before
16.5 dpc (data not shown), the possibility exists that chon-
drocytes are resistant to Snail1 activity until FGFR3 takes
on its role in inhibiting proliferation. The differential ability
of FGFR3 to induce Snail1 and, therefore, the differential
proliferative response to FGFR3 may reflect the different
targets with which it interacts at different developmental
stages.
Snail1 and the Control of Chondrocyte
Differentiation
It has long been established that FGFR3 signals through
the Stat1 pathway in chondrocytes and that it is activated
in achondroplasia (Su et al., 1997). However, although the
loss of Stat1 can rescue proliferation in achondroplastic
mice, the reduced hypertrophic zone or the delay in form-
ing secondary ossification centers is not recovered, only
partly restoring bone length. This suggests the existence
of another pathway regulating longitudinal bone growth.
Indeed, elegant studies carried out by Murakami and
colleagues demonstrated that the achondroplastic phe-
notype is not only the result of Stat activation but also of
MAPK/Mek activation. FGF induces chondrocyte differen-
tiation in a Mek1-dependent manner (Murakami et al.,
2000), and constitutive activation of the MEK1/Erks
provokes Stat1-independent achondroplasia by impairing
hypertrophic chondrocyte differentiation (Murakami et al.,tal Cell 13, 872–883, December 2007 ª2007 Elsevier Inc. 879
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Snail Mediates FGFR3 SignalingFigure 7. Snail1 Inhibition Abolishes FGFR3 Signaling in Chondrocytes and Is Aberrantly Activated in a Human Thanatophoric
Stillborn
Relative mRNA levels for Snail1 (A) and p21 (B) in chondrocyte primary cultures cotransfected with the activating mutations of FGFR3 (ACH G374R;
TDII K644E) alone or in combination with a siRNA against Snail1 (siRNA-3) and/or a plasmid containing the coding region of Snail1 (Snail1 CR). When
Snail1 expression is silenced, the FGF signaling target p21 is not activated (gray bars in [B]). Snail CR overcomes the effect of a Snail1-specific siRNA-3
designed to target 30 untranslated sequences. Snail1 CR increases p21 transcription up to the level obtained upon transfection with the activating
FGFR3 mutants even in the presence of Snail1 siRNA-3 (B). Represented data are the mean ± SD of triplicates from a representative experiment
(n = 4).
(C) Western blot showing the levels of Snail1 protein, Sox9, and activated Erks. Total Erk2 was used as a loading control. Note the increased level of
Snail1, activated Erks, and Sox9 expression in chondrocytes transfected with the activating versions of FGFR3, and the decrease to basal levels of all
three proteins when the cells were cotransfected with siRNA-3. Snail1 CR increases activated Erks and Sox9 expression even in the presence of
siRNA-3.
(D) Diagram showing the two signaling cascades triggered by FGFR3 in chondrocytes. Snail lies upstream of the known readouts of the Stat1 and
MAPK pathways: nuclear Stat1 and p21 activation on one hand, and activated Erks leading to increased Sox9 expression on the other. In the
wild-type condition, the two pathways coordinate chondrocyte proliferation and differentiation. When overstimulated either by activating FGFR3 mu-
tations or through sustained Snail activation, the pathological inhibition of chondrocyte proliferation and differentiation leads to the dwarfism pheno-
type.
(E)Snail1 is aberrantly activated in cartilages from a stillborn bearing the TDII-Fgfr3mutant gene (K650E). TDII, thanatophoric displasia type II stillborn;
N, non-dwarf stillborn bearing the wild-type Fgfr3 gene.2004). Interestingly, the contribution of chondrocyte hy-
pertrophy and matrix synthesis to longitudinal growth is
very significant (Wilsman et al., 1996), explaining the
achondroplasia-like phenotype observed in mice with
constitutively activated Mek-1 in which chondrocyte pro-
liferation is not affected. Our data demonstrate that Snail1
is also required for FGFR3 to activate Erks, indicating that
Snail mediates the signaling by FGFR3 through both the
described pathways. Very recently, constitutive activation
of MKK6, a MAPK that specifically activates p38, has been
shown to delay chondrocyte differentiation and inhibit
proliferation in mice (Zhang et al., 2006). Although in vitro
studies have linked the MAPK/p38 pathway to FGF signal-
ing in chondrocytes (Raucci et al., 2004; Stanton et al.,
2004), this pathway has not been directly linked to
FGFR3 signaling (L’Hoˆte and Knowles, 2005). In relation
to this, the level of activated p38 remained unaffected in
wild-type chondrocytes upon expression of TDII FGFR3,880 Developmental Cell 13, 872–883, December 2007 ª2007and Snail1 activation did not increase activated p38 in
transgenic chondrocytes (Figure S9).
Snail as a Therapeutic Target for Achondroplasia
Snail1 transcripts are very much increased in a stillborn
bearing the most severe and lethal achondroplastic condi-
tion (TDII; K650E). Considering that viable human achon-
droplasia is due to a G380R mutation (98% of the viable
cases [Shiang et al., 1994]), it will be of much interest to
analyze Snail1 expression in a cohort of achondroplastic
patients. It seems likely that Snail1 would also be in-
creased in those patients because, as shown here, the
corresponding mutation in mice (G374R) also induces
elevated levels of Snail1 expression leading to decreased
proliferation and differentiation. If this is the case, the
observed correlation between the achondroplastic phe-
notype and the amount of Snail1 protein in our transgenicElsevier Inc.
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achondroplasia therapies.
The attenuation of FGFR3 signaling has been long
thought to be an effective therapy for achondroplasia,
since it could reconstitute normal bone growth (Aviezer
et al., 2003; Horton, 2006). As such, the C-type natriuretic
peptide (CNP) downregulates the FGF-induced activation
of the MAPK pathway and restores the inhibition of ECM
production in mice (Yasoda et al., 2004). However, CNP
does not affect the Stat1 pathway and thus it will not
restore chondrocyte proliferation to normal levels (Yasoda
et al., 2004). Thus, identifying Snail as an effector mediat-
ing both pathways may help in the design of more effective
therapies.
EXPERIMENTAL PROCEDURES
Transgenic Mice and Snail Activation upon Tamoxifen
Administration
The pcDNA3-Snail1-ERT2 construct contains the Snail1 coding se-
quence fused to a mutated version of the ligand-binding domain of
the human estrogen receptor that recognizes the synthetic ligand
40-OH-Tamoxifen, obtained from the plasmid pCre-ERT2, kindly pro-
vided by P. Chambon (Feil et al., 1996). This construct was used to
generate a tamoxifen-inducible Snail1 transgenic mouse according
to standard procedures (Hogan et al., 1994). A line was selected that
expressed significant levels of the transgenic protein in the developing
bone. The subcellular localization of the protein was assessed by im-
munohistochemistry using a human estrogen-receptor antibody
(Santa Cruz). Genotyping was carried out by PCR, using the primers
50-ACGATAAGCTCGAGCCATCTGC-30 and 50-ACCGAGATGATGTA
GCCAGCAG-30. Tamoxifen (Sigma) was dissolved in corn oil at a final
concentration of 30 mg/ml. Corn oil or 75 mg of Tamoxifen/g of body
weight (Hayashi and McMahon, 2002) was injected intraperitoneally
into pregnant females at 12.5 and 14.5 dpc.
Embryo Dissection and In Situ Hybridization
Embryos were removed at 18.5 dpc and fixed overnight in 4% parafor-
maldehyde. Hindlimbs were decalcified in 22.5% formic acid and 10%
sodium citrate at 4C for 24 hr. Subsequently, they were gelatin
embedded, and 30 mm vibratome sections were obtained. In situ
hybridization was performed as described in Cano et al. (2000), and
the plasmids used to obtain digoxigenin riboprobes corresponded to
the following coding sequences: Snail1 (1–1600 bp), Collagen1a1
(4271–4691 bp), Collagen2a1 (3814–4453 bp), Collagen10a1 (1790–
3744 bp), Pthr1 (1484–4214 bp), and Fgfr3 (3984–4214 bp).
Cartilage and Bone Staining, Histological
and Immunohistochemical Analyses
Embryonic hindlimbs were dissected and fixed overnight in 10%
formalin. Specimens were stained with Alcian Blue to visualize the car-
tilage. Limbs were then trypsinized and stained with Alizarin Red S,
cleared in KOH, and stored in glycerol. Histological sections were ob-
tained from hindlimbs fixed in 10% formalin, decalcified as above, and
either embedded in paraffin (hematoxylin and eosin) or gelatin (immu-
nohistochemistry). Antibodies: a-human estrogen receptor (a-hER,
1:200; Santa Cruz), a-phospho-histone 3 (a-PH3, 1:1000; Upstate),
or a-STAT1 (1:100; Transduction Labs). Immunodetection was carried
out with the biotin-streptavidin system (ABC kit, Pierce) according to
the manufacturer’s instructions.
Chondrocyte Primary Cultures and Transfections
Hindlimbs from wild-type 14.5 dpc mouse embryos were dissected in
a-MEM, 1% BSA, 0.1% L-Glutamine, and 0.1% penicillin/streptomy-
cin and cultured overnight. The following day, the bones were trypsi-Developmenized for 20 min at 37C and digested for 2 hr in 3 mg/ml Collagenase
P in DMEM and 10% FCS at 37C. The digestion medium was
removed and the cells were plated in primary culture media (Woods
and Beier, 2006). After 5 days in culture, the cells were seeded at a den-
sity of 50,000 per well and differentiated to chondrocytes over 5 days in
the presence of 50 ng/ml of BMP2 (Valcourt et al., 1999). Subse-
quently, cells were transfected using Lipofectamine (Invitrogen) with
expression plasmids containing a wild-type or a mutated version of
the FGFR3 cDNA (1.5 mg/well) either alone or in combination with
different Snail1 small interfering RNAs (siRNAs) or the random negative
control. Cells were cultured with or without FGF to activate the recep-
tor, and 72 hr later the cells were collected. The total RNA was purified
from the cells, reverse transcribed, and amplified (Q-RT-PCR), or,
alternatively, protein extracts were obtained for western blot analysis.
The siRNA duplex oligonucleotides were designed as recommended




the Cat. 14750–100 sequence was used as a random siRNA control.
For the MAPKs assays, 14.5 dpc embryo hindlimbs from transgenic
mice were processed as described above, and the differentiated chon-
drocytes were cultured in the absence or presence of 200 nM 4-OHT
(Sigma) and/or FGF. After 24 hr, the cells were collected, and their
RNA or proteins were purified and assayed by Q-RT-PCR or western
blot, respectively. Immunofluorescence was performed on differenti-
ated cells seeded on cover glasses and fixed with ethanol at 20C.
The cells were incubated with a-Collagen I (1:20; Calbiochem), a-Col-
lagen II (1:50; Calbiochem), or a-hER (1:200; Santa Cruz) antibodies.
Real-Time PCR
RNA was isolated using the SIGMA Genelute Total Mammalian RNA
Kit according to the manufacturer’s instructions, and cDNA was syn-
thesized using Super Script III Reverse Transcriptase and Oligo(dT)
primers. Q-PCR was performed using an ABI PRISM 7000 sequence
detection system with the Sybr Green method (primers available on re-
quest). Transcript levels were calculated using the comparative Ct
method normalized to GAPDH. The final results were expressed rela-
tive to a calibrator (wild-type embryos in the absence of Tamoxifen or
mock-transfected cells) using the 2(DDCt) ± SD formula.
Western Blotting
For immunoblotting of total protein, cells were lysed in 50 mM Tris (pH
7.5), 150 mM NaCl, 0.1% SDS, 0.5% Deoxicolate, and 1% Triton X-
100 supplemented with protease inhibitor standard mix (1 mM NaF,
1 mM b-glycero-phosphate, 5 mM NaPPi, 5 mg/ml Leupeptine, 1 mM
Vanadate, and 100 mg/ml PMSF). For the separation of nuclear and
cytosolic proteins, cells were lysed in 10 mM HEPES-K (pH 7.9), 10
mM KCl, 10 mM MgCl2, and 0.5 mM DTT with protease inhibitor mix
to obtain the cytosolic extracts. Pellets were then incubated in 20
mM HEPES-K (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2,
0.5 mM EDTA, 0.5 mM DTT, and protease inhibitor mix. 50 mg of pro-
tein per lane was loaded on a denaturing 12% SDS-PAGE gel. Blots
were incubated with a-phosphorylated ERK1/2 (1:2000; Cell Signal-
ing), a-Sox9 (1:200; Santa Cruz), a-Snail1 (1:200; Abcam), a-Phos-
pho-H3 (1:500, Cell Signaling), a-phospho-p38 (1:1000; Cell Signaling
[Thr180/Tyr182]), or a-total ERK2 (1:500; Santa Cruz) antibodies. The
immunoreactive protein bands were detected using peroxidase-
conjugated secondary antibodies. Quantifications were processed
with the L Process v2.0 program from Bioimager Fujifilm.
Human Tissue Samples
Human cartilage samples were obtained from TDII and normal carti-
lages from stillborn patients. The Research Ethics Committees of our
Institutions approved the protocols to analyze the tissues, which
were processed for real-time RT-PCR as described above.ntal Cell 13, 872–883, December 2007 ª2007 Elsevier Inc. 881
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Supplemental data show the characterization of transgene activation
in preimplantation embryos, the demonstration that Snail1 expression
levels correlate with the achondroplasia phenotype, the absence of
Snail1 effects on chondrocyte cell death, the demonstration that p38
levels are not affected in chondrocytes by aberrant levels of Snail1
or ligand-independent FGF signaling, the expression of Ihh and
PTHrP-R in transgenic Snail1-ER embryos, the maintenance of
FGFR3 expression upon Snail1 activation, the delay in the formation
of secondary ossification centers after Snail1 activation in postnatal
mice, and additional controls for siRNA Snail1 silencing and can be
found with this article online at http://www.developmentalcell.com/
cgi/content/full/13/6/872/DC1/.
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